Remove Clinical Research Remove International Remove Pharmaceuticals Remove Regulations
article thumbnail

Beyond blood tests: The evolution of digital biomarkers in clinical research

Drug Discovery World

Digital biomarkers promise to transform preventive medicine and clinical trials, but also raise issues of security, regulation and potential disparities in access. Deepika Khedekar, Clinical Trial Lead at IQVIA, provides an overview of the pros and cons, and suggests a possible solution.

article thumbnail

Incentivizing Participation: The Evolving Role of Patient Payments in Clinical Research

Vial

Clinical research is an integral component of the healthcare ecosystem. The success of clinical research hinges crucially on patient participation; however, attracting and retaining participants can often pose significant challenges. Patient Payments in Clinical Research: Perception Over the Years In the U.S.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article EMA Thank You What we expect European regulators to do in March 2024

Agency IQ

What we expect European regulators to do in March 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

article thumbnail

A Look Back as the EU Clinical Trial Regulation Moves Forward

PPD

31, 2022, the EU Clinical Trial Regulation (EU CTR) 536/2014 became applicable, heralding a new era for clinical trials in the European Union (EU). Transitioning to EU CTR requirements for existing studies Under the regulation, clinical trial applications submitted before Jan.

article thumbnail

Where is the promise for plant-based medicines? Part 1: Cannabis  

Drug Discovery World

Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains public scepticism, arguably due to the regulations relating to the substance. Jazz Pharmaceuticals has supplied the cannabidiol for the trials at no cost. It’s time to stop borrowing cannabis regulations from other industries.”

article thumbnail

Establishing Effective Adaptive Trial Designs for Oncology in Multi-Regional Studies

Conversations in Drug Development Trends

However, implementing adaptive trial designs within MRCTs requires careful consideration of international regulatory standards to optimize patient outcomes and resource efficiency. Harmonizing regulatory requirements and complying with all relevant regulations are crucial for the success of adaptive MRCTs.

Trials 80
article thumbnail

Q&A with Mark Garner: The golden age of cancer research  

Drug Discovery World

RA: How is Agilent supporting cancer research? MG: Agilent works as closely as we can with the researchers, clinicians, and pharmaceutical companies that are at the forefront of developing therapeutic strategies to understand what they need from a technical point of view. RA: What’s next for cancer research/the industry?

Research 246